drugset / Trial / NCT03585322

APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B

NCT03585322

NaSingle-groupOpen-labelTreatment

Summary

This study is a Multiple Ascending Dose study to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of APG-1387 in Chronic Hepatitis B Patients.

Timeline

Start
2018-07-04
Primary completion
2021-10-15
Completion
2021-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject APG-1387 Small molecule 7 mg Intravenous
Subject APG-1387 Small molecule 12 mg Intravenous
Subject APG-1387 Small molecule 20 mg Intravenous
Subject APG-1387 Small molecule 30 mg Intravenous
Subject APG-1387 Small molecule 45 mg Intravenous